NCT04134325 2026-04-17
Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase EARLY_PHASE1 Active not recruiting
Clinical Trials
12 trialsNCT07302347 2026-04-17
MK-3475-G21
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT03618550 2026-04-16
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05355051 2026-04-15
A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05922904 2026-04-15
PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03240211 2026-04-07
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL
University of Virginia
Phase 1 Active not recruiting
NCT04417166 2026-04-07
Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma
International Extranodal Lymphoma Study Group (IELSG)
Phase 2 Active not recruiting
NCT06242834 2026-04-01
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Northwestern University
Phase 2 Active not recruiting
NCT03983668 2026-03-30
CMP-001 for Relapsed and Refractory Lymphoma
University of Iowa
Phase 1/2 Terminated
NCT03361852 2026-03-25
Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT06863402 2026-03-24
Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT04960618 2026-03-23
Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting